Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...

6, 2025 — The FDA has approved a new implantable treatment for adults with diabetic macular ... reduce swelling in the macula by blocking a protein called VEGF-A, which causes harmful blood ...

The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

The ranibizumab injection delivered through an implant device could be administered in a convenient schedule twice per year ...

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat ...

Susvimo was nonferior to intravitreal ranibizumab based on the change from baseline in distance best corrected visual acuity score. The Food and Drug Administration (FDA) has approved Susvimo ...

Bayer seeks European approval of extended 6-month treatment interval for Eylea 8 mg to treat nAMD & diabetic macular edema: Berlin Tuesday, February 11, 2025, 10:00 Hrs [IST] Baye ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...

100 mg/mL for the treatment of diabetic macular edema (DME), a leading cause of vision loss in adults with diabetes, ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.